We read with great interest the study by Levenick et al entitled, “Rectal Indomethacin Does not Prevent Post-ERCP Pancreatitis in Consecutive Patients.”1 The authors evaluated the efficacy of rectal indomethacin vs placebo for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) in a predominately average risk population (70%) and concluded that it is ineffective for PEP prophylaxis (odds ratio [OR], 1.51; 95% CI, 0.68-3.33). We are concerned about the early termination of the trial by the Data and Safety Monitoring Board after an interim analysis suggested futility of the anticipated primary endpoint.